Heptares $21M Series B Paves Way for Phase I in CNS Disorders
By Nuala Moran
Wednesday, June 26, 2013
LONDON – Heptares Ltd. has raised $21 million in a Series B funding co-led by the Stanley Family Foundation, one of the leading foundations investing in neuroscience diseases. The new funding comes as Heptares is preparing to take its lead program, a first-in-class selective M1 muscarinic receptor agonist into a Phase I trial later this year, paving the way for the product to be developed as a treatment for cognitive impairment in schizophrenia and Alzheimer's disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.